OncoDxRx Emerges from Stealth Mode with World-First PGA Technology
OncoDxRx emerged from stealth mode, saying it is commencing commercial operations with the launch of PGA (Patient-derived Gene expression-informed Anti-cancer drug efficacy) technology, a world-first gene-to-drug platform connecting patient’s gene expression pattern to drug efficacy.
Leveraging the exclusive liquid biopsy knowhow and trade secret, PGA enables laboratories to generate actionable information from blood samples in a 5-day-turnaround workflow, the firm said.
“We have known for years that gene expression (GE) via plasma transcriptomic profiling has the potential to accelerate novel discoveries and advance our understanding of cancer biology and further precision medicine,” the company said in a statement.
PGA enables clinicians and clinical laboratories to access high-resolution anticancer drug efficacy results using cancer type-specific biomarkers and patient-derived GE signature information. The company believes that PGA will take liquid biopsy cell-free mRNA beyond what is possible with current precision oncology testing workup and establish a new industry standard for effective and personalized treatment.
Until now, clinicians considering cancer genomic tests have had to choose between DNA mutations that provide deep coverage at the cost of resolution, or fusions/rearrangements that provide high resolution data across only a subset of targets.
The novel and validated technique on which PGA is based allows regular laboratories to use existing qPCR instrumentation to generate unbiased, high-resolution and actionable data across individual patients who are currently out of targeted therapy or immunotherapy option, unlocking new avenues for personalized treatment.
PGA provides the ability to generate actionable report by molecularly profiling individual patients, obtaining patients’ GE signatures, and in silico screening and matching effective drugs. Oncologists can capture and recognize what the effective drugs are to better decide and optimize treatment strategy, the firm said.
PGA provides a pathway for studying tumor behavior, tumor microenvironment, the immunological response, and the discovery of molecular signatures that predict drug efficacy or treatment response.
It is the first in a suite of one-of-a-kind products that OncoDxRx is developing and validating which enables point-of-treatment using universally existing qPCR instrumentation.
OncoDxRx is currently seeking investors, licensee and partners.
Follow our posts to explore details and updates below:
